Pre-order Enquiry
Request Free Sample
Global Cyclizine Market Insights, Forecast to 2028
SKU ID : QYR-20154120 | Publishing Date : 08-Feb-2022 | No. of pages : 112
Request Sample
Request Customization
Check Discounts
Cyclizine, sold under a number of brand names, is a medication used to treat and prevent nausea, vomiting and dizziness due to motion sickness or vertigo. It may also be used for nausea after general anaesthesia or that which developed from opioid use.
Market Analysis and Insights: Global Cyclizine Market
Due to the COVID-19 pandemic, the global Cyclizine market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Oral accounting for % of the Cyclizine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Migraine segment is altered to an % CAGR throughout this forecast period.
China Cyclizine market size is valued at US$ million in 2021, while the US and Europe Cyclizine are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Cyclizine landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Cyclizine include Amoun Pharmaceutical, Glaxosmithkline, Pharmascript Limited, Advanz Pharma, Teva, P and D Pharmaceuticals, Wabosan Arzneimittel, Aspen Pharmacare and Amco, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Cyclizine Scope and Segment
Cyclizine market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Cyclizine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Oral
Injection
Segment by Application
Migraine
Motion Sickness
By Company
Amoun Pharmaceutical
Glaxosmithkline
Pharmascript Limited
Advanz Pharma
Teva
P and D Pharmaceuticals
Wabosan Arzneimittel
Aspen Pharmacare
Amco
Aft Pharmaceuticals
Be-Tabs Pharmaceuticals
Wockhardt UK
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Market Analysis and Insights: Global Cyclizine Market
Due to the COVID-19 pandemic, the global Cyclizine market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Oral accounting for % of the Cyclizine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Migraine segment is altered to an % CAGR throughout this forecast period.
China Cyclizine market size is valued at US$ million in 2021, while the US and Europe Cyclizine are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Cyclizine landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Cyclizine include Amoun Pharmaceutical, Glaxosmithkline, Pharmascript Limited, Advanz Pharma, Teva, P and D Pharmaceuticals, Wabosan Arzneimittel, Aspen Pharmacare and Amco, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Cyclizine Scope and Segment
Cyclizine market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Cyclizine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Oral
Injection
Segment by Application
Migraine
Motion Sickness
By Company
Amoun Pharmaceutical
Glaxosmithkline
Pharmascript Limited
Advanz Pharma
Teva
P and D Pharmaceuticals
Wabosan Arzneimittel
Aspen Pharmacare
Amco
Aft Pharmaceuticals
Be-Tabs Pharmaceuticals
Wockhardt UK
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
